VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025...DEERFIELD, Ill.--(BUSINESS WIRE)--In light of Rite Aid's recent bankruptcy filing, Walgreens is committed to assisting Rite Aid customers and employees who are impacted by store closures in their local community. For customers who want to transfer their prescriptions to Walgreens: We recognize the trust patients have placed in their Rite Aid pharmacists, and Walgreens is here to continue that care with compassion and consistency. Walgreens is dedicated to meeting patients’ needs for continued a...LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON KRISPY KREME, INC. (DNUT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 25, 2025, Krispy Kreme released its fourth quarte...LOS ANGELES--(BUSINESS WIRE)--Schall Law Firm Announces that it has Filed a Securities Class Action Lawsuit on Behalf of Shareholders of the Digimarc Corporation...LAKELAND, Fla.--(BUSINESS WIRE)--Publix Super Markets, Inc. has initiated a voluntary recall of GreenWise Pear, Kiwi, Spinach & Pea Baby Food, produced by Bowman Andros LLC and distributed to Publix grocery stores in the company’s eight-state operating area. The product is sold in 4-ounce plastic pouches and has the potential to be contaminated with elevated levels of lead. Product Name GTIN Best if Used B...SASKATOON, Saskatchewan--(BUSINESS WIRE)--Cameco (TSX: CCO; NYSE: CCJ) has announced the election of ten board members at its annual meeting held on May 9, 2025. Shareholders elected board members Daniel Camus, Tammy Cook-Searson, Catherine Gignac, Tim Gitzel, Marie Inkster, Kathryn Jackson, Don Kayne, Peter Kukielski, Dominique Minière and Leontine van Leeuwen-Atkins. Voting Results for Cameco Directors Nominee Votes For % Votes For Against % Votes Against Catherine Gignac 70,619,061 97.18% 2,...FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...BRYN MAWR, Pa.--(BUSINESS WIRE)--Aqua Pennsylvania announced it was awarded a combination of grant and low-interest loan funding through the Pennsylvania Infrastructure Investment Authority (PENNVEST). Funding totaling $15.05 million will support Aqua Pennsylvania’s continuing commitment to remove PFAS from drinking water. Another $2.3 million in funding will go toward Aqua Pennsylvania’s ongoing lead service line replacement program. PENNVEST funds allow recipients like Aqua Pennsylvania to co...MIAMI--(BUSINESS WIRE)--Avianca Cargo, a leading cargo carrier in the region, successfully concluded its Mother’s Day 2025 season with a historic record, transporting over 20,100 tons of fresh flowers—a 15% increase compared to last year. The shipments originated from Colombia and Ecuador, reaching destinations across North America and Europe. This achievement reinforces Avianca Cargo’s position as the #1 flower carrier from Colombia to the United States and solidifies its status as one of the...FREDERICKSBURG, Va.--(BUSINESS WIRE)--Obsidian Solutions Group is proud to announce its support to the Western Fire Chiefs Association (WFCA) and its groundbreaking research and development initiative—the Applied Sciences Center for Resilience Studies (ASC). The ASC creates a nexus between researchers and practitioners, enabling and advancing collaboration among government agencies, industries, and academia to enhance community wildfire resilience. ASC’s inaugural research endeavor, which is fu...
Original sourceABCL575 shows potent activity equivalent to advanced clinical benchmarks. Modified Fc domain extends half-life to over 60 days. Positive safety profile and stability, supporting high-dose formulations. ABCL575 could become a best-in-class treatment for atopic dermatitis. Phase 1 clinical trials for ABCL575 expected to start in 2025.
The preclinical data for ABCL575 highlights significant advancements, including potential best-in-class status. Historical data from other biopharma companies indicate similar advancements lead to increased investor confidence and stock price appreciation.
Phase 1 trials are projected for 2025, meaning significant developments could influence long-term growth. Successful clinical trials typically improve market perception and stock performance over time.
The promising data on ABCL575 suggests real potential for therapeutic advancements, making this news highly relevant for ABCL's future stock performance.